Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study
Abstract Background Remdesivir is widely used for treatment of SARS-CoV-2 pneumonia. The aim of this study was to evaluate the characteristics of patients with moderate-to-severe COVID-19 treated with remdesivir, and their outcomes during hospitalization. Methods This retrospective observational mul...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-07-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-023-08422-6 |
| _version_ | 1797784793526566912 |
|---|---|
| author | Filippo Pieralli Fulvio Pomero Francesco Dentali Claudio Norbiato Tiziana Attardo Susanna Vicari Elena Magnani Maria Antonietta Marzilli Paola Piccolo Antonella Valerio Dario Manfellotto on behalf of FADOI RECOVER Study Group |
| author_facet | Filippo Pieralli Fulvio Pomero Francesco Dentali Claudio Norbiato Tiziana Attardo Susanna Vicari Elena Magnani Maria Antonietta Marzilli Paola Piccolo Antonella Valerio Dario Manfellotto on behalf of FADOI RECOVER Study Group |
| author_sort | Filippo Pieralli |
| collection | DOAJ |
| description | Abstract Background Remdesivir is widely used for treatment of SARS-CoV-2 pneumonia. The aim of this study was to evaluate the characteristics of patients with moderate-to-severe COVID-19 treated with remdesivir, and their outcomes during hospitalization. Methods This retrospective observational multicenter study included consecutive patients, hospitalized for moderate-to-severe COVID-19 (September 2020—September 2021), who were treated with remdesivir. Results One thousand four patients were enrolled, all with onset of symptoms occurring less than 10 days before starting remdesivir; 17% of patients had 4 or more concomitant diseases. Remdesivir was well tolerated, adverse drug reactions (ADRs) being reported in 2.3% of patients. In-hospital death occurred in 80 patients (8.0%). The median timing of the first remdesivir dose was 5 days after symptom onset. The following endpoints did not differ according to the time span from the onset of symptoms to the first dose: length of hospitalization, in-hospital death, composite outcome (in-hospital death and/or endotracheal intubation). Advanced age, number of comorbidities ≥ 4, and severity of respiratory failure at admission were associated with poor in-hospital outcomes. Conclusion In a real-world setting, remdesivir proved to be a safe and well-tolerated treatment for moderate-to-severe COVID-19. In patients receiving remdesivir less than 3 or 5 days from the onset of SARS-CoV-2 symptoms, mortality and the need for mechanical ventilation did not differ from the rest of the sample. |
| first_indexed | 2024-03-13T00:44:57Z |
| format | Article |
| id | doaj.art-d36c52b5f9474974b682df53bfa3208c |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-03-13T00:44:57Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-d36c52b5f9474974b682df53bfa3208c2023-07-09T11:07:40ZengBMCBMC Infectious Diseases1471-23342023-07-012311810.1186/s12879-023-08422-6Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER studyFilippo Pieralli0Fulvio Pomero1Francesco Dentali2Claudio Norbiato3Tiziana Attardo4Susanna Vicari5Elena Magnani6Maria Antonietta Marzilli7Paola Piccolo8Antonella Valerio9Dario Manfellotto10on behalf of FADOI RECOVER Study GroupInternal Medicine and Intermediate Care Unit, Careggi University HospitalInternal Medicine, Michele and Pietro Ferrero HospitalDepartment of Emergency of High-Specialty and Medical Center, ASST-SettelaghiInternal Medicine, Ordine Mauriziano di Torino HospitalInternal Medicine Department, Ospedale di Circolo e Fondazione Macchi, ASST-SettelaghiInternal Medicine, Bentivoglio Hospital, AUSL BolognaInternal Medicine, M. Bufalini Hospital, AUSL RomagnaInternal Medicine Department, SS. Trinità HospitalInternal Medicine, Fatebenefratelli Isola Tiberina Hospital, Gemelli IsolaResearch Department, FADOI FoundationInternal Medicine, Fatebenefratelli Isola Tiberina Hospital, Gemelli IsolaAbstract Background Remdesivir is widely used for treatment of SARS-CoV-2 pneumonia. The aim of this study was to evaluate the characteristics of patients with moderate-to-severe COVID-19 treated with remdesivir, and their outcomes during hospitalization. Methods This retrospective observational multicenter study included consecutive patients, hospitalized for moderate-to-severe COVID-19 (September 2020—September 2021), who were treated with remdesivir. Results One thousand four patients were enrolled, all with onset of symptoms occurring less than 10 days before starting remdesivir; 17% of patients had 4 or more concomitant diseases. Remdesivir was well tolerated, adverse drug reactions (ADRs) being reported in 2.3% of patients. In-hospital death occurred in 80 patients (8.0%). The median timing of the first remdesivir dose was 5 days after symptom onset. The following endpoints did not differ according to the time span from the onset of symptoms to the first dose: length of hospitalization, in-hospital death, composite outcome (in-hospital death and/or endotracheal intubation). Advanced age, number of comorbidities ≥ 4, and severity of respiratory failure at admission were associated with poor in-hospital outcomes. Conclusion In a real-world setting, remdesivir proved to be a safe and well-tolerated treatment for moderate-to-severe COVID-19. In patients receiving remdesivir less than 3 or 5 days from the onset of SARS-CoV-2 symptoms, mortality and the need for mechanical ventilation did not differ from the rest of the sample.https://doi.org/10.1186/s12879-023-08422-6RemdesivirInternal MedicineCOVID-19 pneumoniaManagement of COVID-19 |
| spellingShingle | Filippo Pieralli Fulvio Pomero Francesco Dentali Claudio Norbiato Tiziana Attardo Susanna Vicari Elena Magnani Maria Antonietta Marzilli Paola Piccolo Antonella Valerio Dario Manfellotto on behalf of FADOI RECOVER Study Group Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study BMC Infectious Diseases Remdesivir Internal Medicine COVID-19 pneumonia Management of COVID-19 |
| title | Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study |
| title_full | Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study |
| title_fullStr | Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study |
| title_full_unstemmed | Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study |
| title_short | Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study |
| title_sort | real world use of remdesivir for the treatment of patients admitted to italian hospitals with covid 19 the nationwide retrospective fadoi recover study |
| topic | Remdesivir Internal Medicine COVID-19 pneumonia Management of COVID-19 |
| url | https://doi.org/10.1186/s12879-023-08422-6 |
| work_keys_str_mv | AT filippopieralli realworlduseofremdesivirforthetreatmentofpatientsadmittedtoitalianhospitalswithcovid19thenationwideretrospectivefadoirecoverstudy AT fulviopomero realworlduseofremdesivirforthetreatmentofpatientsadmittedtoitalianhospitalswithcovid19thenationwideretrospectivefadoirecoverstudy AT francescodentali realworlduseofremdesivirforthetreatmentofpatientsadmittedtoitalianhospitalswithcovid19thenationwideretrospectivefadoirecoverstudy AT claudionorbiato realworlduseofremdesivirforthetreatmentofpatientsadmittedtoitalianhospitalswithcovid19thenationwideretrospectivefadoirecoverstudy AT tizianaattardo realworlduseofremdesivirforthetreatmentofpatientsadmittedtoitalianhospitalswithcovid19thenationwideretrospectivefadoirecoverstudy AT susannavicari realworlduseofremdesivirforthetreatmentofpatientsadmittedtoitalianhospitalswithcovid19thenationwideretrospectivefadoirecoverstudy AT elenamagnani realworlduseofremdesivirforthetreatmentofpatientsadmittedtoitalianhospitalswithcovid19thenationwideretrospectivefadoirecoverstudy AT mariaantoniettamarzilli realworlduseofremdesivirforthetreatmentofpatientsadmittedtoitalianhospitalswithcovid19thenationwideretrospectivefadoirecoverstudy AT paolapiccolo realworlduseofremdesivirforthetreatmentofpatientsadmittedtoitalianhospitalswithcovid19thenationwideretrospectivefadoirecoverstudy AT antonellavalerio realworlduseofremdesivirforthetreatmentofpatientsadmittedtoitalianhospitalswithcovid19thenationwideretrospectivefadoirecoverstudy AT dariomanfellotto realworlduseofremdesivirforthetreatmentofpatientsadmittedtoitalianhospitalswithcovid19thenationwideretrospectivefadoirecoverstudy AT onbehalfoffadoirecoverstudygroup realworlduseofremdesivirforthetreatmentofpatientsadmittedtoitalianhospitalswithcovid19thenationwideretrospectivefadoirecoverstudy |